Amarin Corporation PLC at JPMorgan Healthcare Conference Transcript
Hello. My name is Daniel Wolle. I'm one of the SMid-Cap Biotech Analyst at JPM. It's my pleasure to introduce Karim Mikhail from Amarin. Without further ado.
Good afternoon, everyone. I just want to start by thanking Daniel and JPMorgan for inviting us for the conference to share with you the progress we've made in 2020, '22 against solid through bold objectives that we've had. 2022 started as a challenging year where we've had the third generic, we had an impact on revenue. But we are closing the year with 4 consecutive quarters of revenue in the U.S., a positive cash burn in Q4, but also 5 markets where we have final pricing and reimbursement in Europe. So in my presentation, I may make forward-looking statements or a full list of risk factors, please consult our SEC filing.
So my presentation is going to have 4 main portions. I will start first by just reviewing a little bit of the Amarin journey, where we have
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
